ES2564010T3 - Composición farmacéutica para tratar o prevenir el glaucoma - Google Patents
Composición farmacéutica para tratar o prevenir el glaucoma Download PDFInfo
- Publication number
- ES2564010T3 ES2564010T3 ES10758728.9T ES10758728T ES2564010T3 ES 2564010 T3 ES2564010 T3 ES 2564010T3 ES 10758728 T ES10758728 T ES 10758728T ES 2564010 T3 ES2564010 T3 ES 2564010T3
- Authority
- ES
- Spain
- Prior art keywords
- group
- halogen
- alkyl
- alkoxy
- substituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 208000010412 Glaucoma Diseases 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 229910052736 halogen Inorganic materials 0.000 abstract 6
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 3
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 3
- 125000005843 halogen group Chemical group 0.000 abstract 3
- 125000003118 aryl group Chemical group 0.000 abstract 2
- 125000006700 (C1-C6) alkylthio group Chemical group 0.000 abstract 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 125000000732 arylene group Chemical group 0.000 abstract 1
- 125000004429 atom Chemical group 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000001072 heteroaryl group Chemical group 0.000 abstract 1
- 125000005549 heteroarylene group Chemical group 0.000 abstract 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 239000004615 ingredient Substances 0.000 abstract 1
- 229940054534 ophthalmic solution Drugs 0.000 abstract 1
- 239000002997 ophthalmic solution Substances 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000000243 solution Substances 0.000 abstract 1
- 238000011282 treatment Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/83—Thioacids; Thioesters; Thioamides; Thioimides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Ophthalmology & Optometry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2009082725 | 2009-03-30 | ||
| JP2009082725 | 2009-03-30 | ||
| PCT/JP2010/055719 WO2010113957A1 (ja) | 2009-03-30 | 2010-03-30 | 緑内障の治療又は予防のための医薬組成物 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2564010T3 true ES2564010T3 (es) | 2016-03-17 |
Family
ID=42828246
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES10758728.9T Active ES2564010T3 (es) | 2009-03-30 | 2010-03-30 | Composición farmacéutica para tratar o prevenir el glaucoma |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US8685986B2 (de) |
| EP (1) | EP2415763B1 (de) |
| JP (2) | JP5300033B2 (de) |
| KR (1) | KR101681347B1 (de) |
| CN (1) | CN102448940B (de) |
| AU (1) | AU2010231630B2 (de) |
| CA (1) | CA2757291C (de) |
| CY (1) | CY1117193T1 (de) |
| DK (1) | DK2415763T3 (de) |
| ES (1) | ES2564010T3 (de) |
| HK (1) | HK1170490A1 (de) |
| HR (1) | HRP20160104T1 (de) |
| HU (1) | HUE026742T2 (de) |
| PL (1) | PL2415763T3 (de) |
| PT (1) | PT2415763E (de) |
| SI (1) | SI2415763T1 (de) |
| SM (1) | SMT201600055B (de) |
| WO (1) | WO2010113957A1 (de) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103965099A (zh) * | 2008-03-12 | 2014-08-06 | 宇部兴产株式会社 | 吡啶基氨基乙酸化合物 |
| DK2415763T3 (en) | 2009-03-30 | 2016-03-07 | Ube Industries | A pharmaceutical composition for the treatment or prevention of glaucoma |
| JP2011057633A (ja) * | 2009-09-11 | 2011-03-24 | Ube Industries Ltd | ピリジルアミノ酢酸化合物を含有する医薬 |
| US20120226036A1 (en) * | 2009-09-11 | 2012-09-06 | Ube Industries, Ltd. | Substituted carbonyl compound |
| KR20120101722A (ko) | 2009-12-25 | 2012-09-14 | 우베 고산 가부시키가이샤 | 아미노피리딘 화합물 |
| US9339496B2 (en) | 2012-07-13 | 2016-05-17 | Santen Pharmaceutical Co., Ltd. | Composition for treating or preventing glaucoma comprising a sulfonamide compound, and a beta-receptor antagonist |
| CA3099517C (en) * | 2012-07-13 | 2022-04-26 | Santen Pharmaceutical Co., Ltd. | Combinations comprising a sulfonamide compound for the treatment of glaucoma or ocular hypertension |
| CN105308023A (zh) * | 2013-03-28 | 2016-02-03 | 宇部兴产株式会社 | 取代联芳基化合物 |
| KR101858373B1 (ko) * | 2014-01-10 | 2018-05-15 | 산텐 세이야꾸 가부시키가이샤 | 피리딜아미노아세트산 화합물과 폴리옥시에틸렌 피마자유를 함유하는 의약 조성물 |
| EP3093019B1 (de) * | 2014-01-10 | 2021-05-26 | Santen Pharmaceutical Co., Ltd | Pharmazeutische zusammensetzung mit pyridylaminoessigsäureverbindung |
| UA117506C2 (uk) * | 2014-01-10 | 2018-08-10 | Сантен Фармас'Ютікал Ко., Лтд. | Фармацевтичний препарат, який містить сполуку піридиламінооцтової кислоти |
| US10774072B2 (en) | 2014-06-10 | 2020-09-15 | Ube Industries, Ltd. | Crystal of N-substituted sulfonamide compound |
| WO2015190507A1 (ja) * | 2014-06-10 | 2015-12-17 | 宇部興産株式会社 | Ｎ－置換スルホンアミド化合物およびその製造方法 |
| US10519112B2 (en) | 2014-06-10 | 2019-12-31 | Ube Industries, Ltd. | Method for producing heteroaromatic sulfonamide compound |
| JP2017206445A (ja) * | 2014-09-26 | 2017-11-24 | 宇部興産株式会社 | 呼吸器疾患の治療及び／又は予防のための医薬組成物 |
| AR105215A1 (es) * | 2015-07-01 | 2017-09-13 | Santen Pharmaceutical Co Ltd | Formulación de depósito que contiene ésteres de ácido cítrico |
| ES2950461T3 (es) * | 2015-07-09 | 2023-10-10 | Santen Pharmaceutical Co Ltd | Agente preventivo y/o terapéutico que contiene un compuesto de ácido piridilaminoacético para el tratamiento de una enfermedad que involucra una presión intraocular muy elevada |
| US10940144B2 (en) * | 2017-09-29 | 2021-03-09 | Santen Pharmaceutical Co., Ltd. | Drug containing pyridylaminoacetic acid compound |
| US20210106569A1 (en) | 2017-12-21 | 2021-04-15 | Santen Pharmaceutical Co., Ltd. | Omidenepag combination |
| WO2019124488A1 (ja) | 2017-12-21 | 2019-06-27 | 参天製薬株式会社 | セペタプロストとＲｈｏキナーゼ阻害剤との組み合わせ医薬 |
| JP7346305B2 (ja) * | 2017-12-28 | 2023-09-19 | 参天製薬株式会社 | ピリジルアミノ酢酸化合物を含有する医薬製剤 |
| KR20220089106A (ko) | 2020-12-21 | 2022-06-28 | 이성규 | 도르졸라마이드 또는 폴리소르베이트80을 유효성분으로 포함하는 점안용 조성물 |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW523506B (en) | 1996-12-18 | 2003-03-11 | Ono Pharmaceutical Co | Sulfonamide or carbamide derivatives and drugs containing the same as active ingredients |
| UA59384C2 (uk) | 1996-12-20 | 2003-09-15 | Пфайзер, Інк. | Похідні сульфонамідів та амідів як агоністи простагландину, фармацевтична композиція та способи лікування на їх основі |
| UA67754C2 (uk) | 1997-10-10 | 2004-07-15 | Пфайзер, Інк. | Агоністи простагландину, фармацевтична композиція на їх основі (варіанти), спосіб нарощення та збереження кісткової маси у хребетних та спосіб лікування (варіанти) |
| ATE346050T1 (de) | 1998-01-27 | 2006-12-15 | Aventis Pharma Inc | Substituierte oxoazaheterocyclyl faktor xa hemmer |
| WO2002024647A1 (fr) | 2000-09-21 | 2002-03-28 | Ono Pharmaceutical Co., Ltd. | Agonistes du recepteur de l'ep4 comprenant comme principe actif des derives de la 8-azaprostaglandine |
| JP4529119B2 (ja) | 2001-08-09 | 2010-08-25 | 小野薬品工業株式会社 | カルボン酸誘導体化合物およびその化合物を有効成分として含有する薬剤 |
| ES2259010T3 (es) | 2001-10-26 | 2006-09-16 | Allergan, Inc. | Analogos de omega-cicloalquil-17-heteroaril-prostaglandina e2 como agonistas del receptor ep2. |
| HUP0500012A2 (hu) | 2002-01-31 | 2005-04-28 | Pfizer Products Inc. | A (3-{[4-terc-butil-benzil)-(piridin-3-szulfonil)-amino]-metil}-fenoxi)-ecetsav metabolitjai és ezeket hatóanyagként tartalmazó gyógyszerkészítmények |
| JP4547912B2 (ja) | 2002-03-05 | 2010-09-22 | 小野薬品工業株式会社 | ８−アザプロスタグランジン誘導体化合物およびその化合物を有効成分として含有する薬剤 |
| US20070000939A1 (en) | 2002-10-29 | 2007-01-04 | Vasilios Vasiadis | Device for handling and orientating pills or tablets in a precise manner |
| CA2518193A1 (en) * | 2003-03-04 | 2004-09-16 | Pfizer Products Inc. | Use of ep2 selective receptor agonists in medical treatment |
| GB0329620D0 (en) | 2003-12-22 | 2004-01-28 | Pharmagene Lab Ltd | EP2 receptor agonists |
| JP2007186424A (ja) | 2004-11-26 | 2007-07-26 | Ono Pharmaceut Co Ltd | 気管支拡張剤 |
| WO2005072743A1 (ja) | 2004-01-30 | 2005-08-11 | Ono Pharmaceutical Co., Ltd. | 気管支拡張剤 |
| US7994196B2 (en) | 2004-02-12 | 2011-08-09 | Mitsubishi Tanabe Pharma Corporation | Indazole compound and pharmaceutical use thereof |
| EP1593671A1 (de) | 2004-03-05 | 2005-11-09 | Graffinity Pharmaceuticals AG | DPP-IV Inhibitoren |
| EP1765332A2 (de) * | 2004-06-17 | 2007-03-28 | Cengent Therapeutics, Inc. | Trisubstituierte stickstoffmodulatoren von tyrosin-phosphatasen |
| GB0415320D0 (en) | 2004-07-08 | 2004-08-11 | Astrazeneca Ab | Novel compounds |
| ES2346685T3 (es) | 2005-01-14 | 2010-10-19 | F. Hoffmann-La Roche Ag | Deribados de tiazol-4-carboxamida como antagonistas de mglur5. |
| JP4874958B2 (ja) | 2005-03-30 | 2012-02-15 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | ピリジン誘導体を含有する抗真菌剤 |
| AU2006275263A1 (en) | 2005-08-03 | 2007-02-08 | Merck Frosst Canada Ltd | EP4 receptor agonist, compositions and methods thereof |
| AU2006277786B2 (en) | 2005-08-09 | 2012-09-06 | Asterand Uk Acquisition Limited | EP2 receptor agonists |
| US7696235B2 (en) | 2005-08-29 | 2010-04-13 | Allergan, Inc. | EP2 receptor agonists for treating glaucoma |
| NZ573964A (en) | 2006-07-28 | 2010-11-26 | Pfizer Prod Inc | isopropyl [3-({[4-(1H-pyrazol-1-yl)benzyl](pyridin-3-ylsulfonyl)-amino}methyl)phenoxy]acetate, a prostaglandin E2 receptor agonist (EP2), useful in lower intraocular pressure thereby treating glaucoma |
| FI123744B (fi) * | 2006-09-06 | 2013-10-15 | Sandvik Mining & Constr Oy | Menetelmä kallion poraamiseksi |
| CN103965099A (zh) * | 2008-03-12 | 2014-08-06 | 宇部兴产株式会社 | 吡啶基氨基乙酸化合物 |
| DK2415763T3 (en) | 2009-03-30 | 2016-03-07 | Ube Industries | A pharmaceutical composition for the treatment or prevention of glaucoma |
-
2010
- 2010-03-30 DK DK10758728.9T patent/DK2415763T3/en active
- 2010-03-30 SI SI201031130A patent/SI2415763T1/sl unknown
- 2010-03-30 PL PL10758728T patent/PL2415763T3/pl unknown
- 2010-03-30 PT PT107587289T patent/PT2415763E/pt unknown
- 2010-03-30 HU HUE10758728A patent/HUE026742T2/en unknown
- 2010-03-30 EP EP10758728.9A patent/EP2415763B1/de active Active
- 2010-03-30 CA CA2757291A patent/CA2757291C/en active Active
- 2010-03-30 JP JP2011507220A patent/JP5300033B2/ja active Active
- 2010-03-30 ES ES10758728.9T patent/ES2564010T3/es active Active
- 2010-03-30 WO PCT/JP2010/055719 patent/WO2010113957A1/ja active Application Filing
- 2010-03-30 KR KR1020117025638A patent/KR101681347B1/ko active IP Right Grant
- 2010-03-30 AU AU2010231630A patent/AU2010231630B2/en active Active
- 2010-03-30 CN CN201080023601.4A patent/CN102448940B/zh active Active
- 2010-03-30 US US13/260,946 patent/US8685986B2/en active Active
-
2012
- 2012-11-09 HK HK12111327.7A patent/HK1170490A1/zh unknown
-
2013
- 2013-04-08 JP JP2013080307A patent/JP5556924B2/ja active Active
-
2016
- 2016-01-29 HR HRP20160104T patent/HRP20160104T1/hr unknown
- 2016-02-15 CY CY20161100125T patent/CY1117193T1/el unknown
- 2016-02-24 SM SM201600055T patent/SMT201600055B/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA2757291C (en) | 2017-05-23 |
| JP5300033B2 (ja) | 2013-09-25 |
| JP2013151548A (ja) | 2013-08-08 |
| KR101681347B1 (ko) | 2016-11-30 |
| HRP20160104T1 (hr) | 2016-03-25 |
| PL2415763T3 (pl) | 2016-05-31 |
| CN102448940B (zh) | 2015-10-21 |
| AU2010231630A1 (en) | 2011-11-10 |
| EP2415763A4 (de) | 2012-08-15 |
| AU2010231630B2 (en) | 2015-02-12 |
| US8685986B2 (en) | 2014-04-01 |
| SMT201600055B (it) | 2016-04-29 |
| EP2415763A1 (de) | 2012-02-08 |
| WO2010113957A1 (ja) | 2010-10-07 |
| KR20120003475A (ko) | 2012-01-10 |
| US20120190852A1 (en) | 2012-07-26 |
| HUE026742T2 (en) | 2016-07-28 |
| CY1117193T1 (el) | 2017-04-05 |
| JPWO2010113957A1 (ja) | 2012-10-11 |
| CN102448940A (zh) | 2012-05-09 |
| PT2415763E (pt) | 2016-03-30 |
| DK2415763T3 (en) | 2016-03-07 |
| JP5556924B2 (ja) | 2014-07-23 |
| CA2757291A1 (en) | 2010-10-07 |
| SI2415763T1 (sl) | 2016-05-31 |
| HK1170490A1 (zh) | 2013-03-01 |
| EP2415763B1 (de) | 2016-01-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2564010T3 (es) | Composición farmacéutica para tratar o prevenir el glaucoma | |
| AR114164A1 (es) | Piridopirimidinonas sustituidas con bencilamino y derivados como inhibidores de sos1 | |
| AR050952A1 (es) | Derivados de indazolona; procesos para su obtencion; composiciones farmaceuticas que los contienen y su uso en la fabricacion de medicamentos para el tratamiento de enfermedades mediadas por la inhibicion de la enzima 11beta - hsd1. | |
| AR077935A1 (es) | Derivados de 3-amino-5 fenil-5,6-dihidro-2h-(1,4)oxazina | |
| PE20170666A1 (es) | 2-(morfolin-4-il)-1,7-naftiridinas | |
| PE20160540A1 (es) | Inhibidores de bromodominios | |
| PE20141110A1 (es) | Derivados heterociclicos novedosos para el tratamiento de trastornos neurologicos | |
| EA201691428A1 (ru) | Бициклические гетероциклические производные в качестве ингибиторов irak4 | |
| NI201000145A (es) | DERIVADOS DE IMIDAZO - [1, 2-b] - PIRIDAZINA PARA EL TRATAMIENTO DE ENFERMEDAD MEDIADA POR CINASA DE TIROSINA C-MET. | |
| AR089781A1 (es) | Fluorometil-5,6-dihidro-4h-[1,3]oxazinas | |
| MX2015009057A (es) | Compuestos de tiazolcarboxamidas y piridinacarboxamida utiles como inhibidores de cinasa pim. | |
| TN2014000062A1 (en) | 2 -amino-4 - (pyridin- 2 -yl) - 5, 6 -dihydro-4h- 1, 3 -oxazine derivatives and their use as bace-1 and/or bace - 2 inhibitors | |
| UY32462A (es) | Derivados de bifenilo novedosos para el tratamiento de infección por virus de hepatitis c 644 | |
| AR054560A1 (es) | Espiropiperidina como inhibidores de beta-secretasa para el tratamiento de la enfermedad de alzheimer | |
| AR070395A1 (es) | Derivados de 4,5-dihidro-oxazol-2-il- amina | |
| EA201071370A1 (ru) | Серосодержащее гетероциклическое производное, обладающее активностью ингибитора бета-секретазы | |
| AR087915A1 (es) | N-(3-(2-amino-6,6-difluor-4,4a,5,6,7,7a-hexahidro-ciclopenta-[e][1,3]oxazin-4-il)-fenil)-amidas como inhibidores de la bace1 | |
| WO2013174930A2 (en) | 7-oxo-thiazolopyridine carbonic acid derivatives and their use in the treatment, amelioration or prevention of a viral disease | |
| MX2012002179A (es) | Compuestos heterociclicos de oxima. | |
| PE20190968A1 (es) | Compuestos de heterociclo tetraciclicos utiles como inhibidores de la integrasa del vih | |
| ATE473221T1 (de) | 1-(1-benzylpiperidin-4-yl)benzimidazol-5- carbonsäurederivate zur behandlung von diabetes mellitus | |
| ECSP088963A (es) | Aminopirazolopiridinas sustituidas y sus sales, sus preparaciones y composiciones farmacéuticas que las comprenden | |
| AR061583A1 (es) | Acidos 6-(bencilo sustituido con heterociclil)-4-oxiquinolin carboxilicos, inhibidores de vih-integrasas, composiciones farmaceuticas que los contienen y usos como agentes anti-vih. | |
| EA202192900A1 (ru) | Модуляторы пути интегрированной реакции на стресс | |
| PE20160934A1 (es) | (aza) piridopirazolopirimidinonas e indazolopirimidinonas como inhibidores de fibrinolisis |